Table I.
Prevalence of p62 positivity and the pattern of staining among different clinical subgroups.
| Myositis | Comparators | Histologically normal (n=29) | |||||
|---|---|---|---|---|---|---|---|
| sIBM (n=37) | IMNM (n=31) | DM (n=40) | PM (n=28) | Neurogenic disorders (n=85) | Other myopathies (n=53) | ||
| p62 positive | 92% (34) | 87% (27) | 57% (23) | 29% (8) | 31% (26) | 26% (14) | 0% (0) |
| p62 subsarcolemmal aggregates | 76% (28) | 55% (17) | 28% (11) | 7% (2) | 14% (12) | 13% (7) | 0% (0) |
| p62 sarcoplasmic aggregates | 73% (27) | 68% (21) | 32% (13) | 14% (4) | 19% (16) | 15% (8) | 0% (0) |
| p62 punctate pattern | 51% (19) | 61% (19) | 40% (16) | 25% (7) | 14% (12) | 21% (11) | 0% (0) |
| p62 circumscribed punctuation | 3% (1) | 0% (0) | 0% (0) | 4% (1) | 4% (3) | 0% (0) | 0% (0) |
| p62 perivacuolar | 19% (7) | 0% (0) | 0% (0) | 0% (0) | 4% (3) | 6% (3) | 0% (0) |
| p62 necrotic cells | 3% (1) | 55% (17) | 2% (1) | 4% (1) | 2% (2) | 2% (1) | 0% (0) |
| p62 perifascicular | 0% (0) | 0% (0) | 32% (13) | 11% (3) | 0% (0) | 0% (0) | 0% (0) |